Cyclica (acquired by Recursion, Nasdaq: RXRX)
Cyclica (acquired by Recursion, Nasdaq: RXRX)'s Overview
Cyclica is a Toronto-based biotechnology company that is decentralizing drug discovery by leveraging artificial intelligence (AI) and computational biophysics. Their proprietary platforms, including Ligand Design™ for novel molecule generation and Ligand Express® for polypharmacology profiling, aim to create safer, more effective medicines faster. Cyclica partners with pharmaceutical and biotechnology companies to advance their research pipelines and focuses on a drug's polypharmacology – how it interacts with multiple protein targets – to design therapies with improved efficacy and reduced side effects.
Where is Cyclica (acquired by Recursion, Nasdaq: RXRX)'s Headquarters?
HQ Function
The headquarters serves as the central hub for Cyclica's research and development, AI platform innovation, business operations, and strategic partnerships.
Notable Features:
Located within the MaRS Discovery District, providing access to a vibrant ecosystem of researchers, startups, and established companies in the life sciences sector. Modern office and computational lab facilities designed for collaboration and innovation.
Work Culture:
Cyclica fosters a dynamic, innovative, and collaborative work culture focused on scientific excellence, technological advancement, and a shared mission to impact human health. Employees are typically mission-driven and passionate about drug discovery.
HQ Significance:
The MaRS location provides Cyclica with unparalleled access to talent, research institutions, potential collaborators, and resources, positioning it at the forefront of Canada's biotech innovation landscape.
Values Reflected in HQ: The headquarters at MaRS, a hub of innovation, reflects Cyclica's commitment to cutting-edge science, collaboration with the broader research community, and the pursuit of transformative solutions in healthcare.
Location:
While headquartered in Toronto, Cyclica has a global reach through its partnerships with pharmaceutical and biotechnology companies worldwide. Their AI-driven drug discovery platforms support research and development efforts internationally, enabling collaborations across different geographies to advance therapeutic programs.
Street Address:
MaRS Centre, West Tower, 101 College Street, Suite (e.g. specific suite if known, otherwise general MaRS address)
City:
Toronto
State/Province:
Ontario
Country:
Canada
Cyclica (acquired by Recursion, Nasdaq: RXRX)'s Global Presence
Buying Intent Signals for Cyclica (acquired by Recursion, Nasdaq: RXRX)
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Cyclica (acquired by Recursion, Nasdaq: RXRX)
As of April 2025, Cyclica (acquired by Recursion, Nasdaq: RXRX)' leadership includes:
Investors of Cyclica (acquired by Recursion, Nasdaq: RXRX)
Cyclica (acquired by Recursion, Nasdaq: RXRX) has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Cyclica's core executive leadership team has demonstrated stability over the past 12 months, with no major publicly announced C-suite hires or departures. The company continues to be led by its established team in advancing its AI-driven drug discovery platforms.
Technology (Tech Stack) used by Cyclica (acquired by Recursion, Nasdaq: RXRX)
Discover the tools Cyclica (acquired by Recursion, Nasdaq: RXRX) uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cyclica (acquired by Recursion, Nasdaq: RXRX) Email Formats and Examples
Common email formats for Cyclica likely follow standard professional patterns. While specific internal structures can vary, a typical format would involve the first initial and last name, or first name and last name separated by a dot.
[first_initial][last]@cyclicarx.com
Format
nkurji@cyclicarx.com
Example
85%
Success rate
News and media
Canada Newswire via Yahoo Finance • June 20, 2023
Cyclica and Servier Canada announce a strategic partnership to accelerate drug discovery for rare neurological diseases
Cyclica and Servier Canada have partnered to utilize Cyclica's AI-driven drug discovery platform to identify and design novel drug candidates for rare neurological diseases, aiming to accelerate the development of new treatments....more
PR Newswire • March 14, 2023
Cyclica Announces Close of CAD $3.2M in Non-Dilutive Funding Through Government Programs
Cyclica secured CAD $3.2 million in non-dilutive funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) and a Scientific Research and Experimental Development (SR&ED) tax credit refund. This funding supports the advancement of its AI drug discovery platform and R&D activities....more
Business Wire • October 26, 2022
Cyclica Launches Stimulating Innovation in Drug Discovery Initiative to Drive Early-Stage Research Globally
Cyclica announced the launch of its 'Stimulating Innovation in Drug Discovery' initiative, providing academic and research institutions with access to its AI-powered drug discovery platforms, Ligand Design and Ligand Express, to foster early-stage research and innovation....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Cyclica (acquired by Recursion, Nasdaq: RXRX), are just a search away.